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Abstract 
Introduction: Women with polycystic ovary syndrome (PCOS) have a 3-fold higher risk of 
endometrial cancer (EC). Insulin resistance and hyperlipidaemia may be pertinent factors in 
the pathogenesis of both conditions. The aim of this study was to investigate endometrial 
Sterol Regulatory Element Binding Protein-1 gene (SREBP1) expression in PCOS and EC 
endometrium, and to correlate endometrial SREBP1 expression with serum lipid profiles. 
Material and methods: A cross-sectional study was performed at Nottingham University 
Hospital, United Kingdom. A total of 102 women (PCOS, EC and controls; 34 participants in 
each group) were recruited. Clinical and biochemical assessments were performed before 
endometrial biopsies were obtained from all participants. Taqman real-time PCR for 
endometrial SREBP1 and its systemic protein expression were analysed. Results: The BMI of 
women with PCOS (29.28 (±2.91) kg/m2) and controls (28.58 (±2.62) kg/m2) was not 
significantly different. Women with EC had a higher mean BMI (32.22 (±5.70) kg/m2). 
SREBP1 gene expression was significantly increased in PCOS and EC endometrium 
compared to controls (p<0.0001). SREBP1 gene expression was positively correlated with 
BMI (r=0.017, p=0.921) and waist-hip ratio (r=0.023, p=0.544) in PCOS, but this was not 
statistically significant.  Similarly, statistically insignificant positive correlations were found 
between endometrial SREBP1 gene expression and BMI in EC (r=0.643, p=0.06) and waist-
hip ratio (r=0.096, p=0.073). SREBP1 expression was significantly positively correlated with 
triglyceride in both PCOS and EC (p= 0.028 and p=0.027). Quantitative serum SREBP1 
correlated with endometrial gene expression (p<0.05). Conclusions: SREBP1 gene expression 
is significantly increased in the endometrium of PCOS and EC women compared with 
controls and positively correlates with serum triglyceride in both PCOS and EC.  
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Key Message 
Women with PCOS are at a higher risk of developing endometrial cancer, due to increased 
endometrial lipogenesis, resulting from increased SREBP1 expression. 
 
List of abbreviations 
ACTB: beta actin gene 
BMI: body mass index 
EC: endometrial cancer 
FSH: Follicle stimulating hormone 
G1: Grade 1 (well differentiated) 
G2: Grade 2 (moderately differentiated) 
G3: Grade 3 (poorly differentiated) 
HDL: high density lipoprotein 
HOMA-IR: homeostatic model assessment of insulin resistance 
IGF1: insulin-like growth factor-1 
IGFBP1: insulin-like growth factor binding protein 1 
PTEN phosphatase and tensin homolog  
LH: leutinizing hormone 
PCOS: polycystic ovary syndrome 
SREBP1: sterol regulatory element binding protein-1gene 
WHR: waist-hip ratio 
 
Introduction 
 
Polycystic ovary syndrome (PCOS) is a complex hormonal and metabolic disorder that 
affects women of reproductive age. It is estimated that about 5-10% (1) of women of 
reproductive age, are diagnosed with this condition. Other than being associated with a poor 
fertility outcome and an increased risk of cardiovascular disease, PCOS has also been 
associated with an increased risk of endometrial cancer (EC). Women with PCOS have a 3 to 
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4 fold increased risk of EC compared with women without PCOS, the large majority of which 
being type 1 EC (2,3). The exact molecular mechanisms linking PCOS and EC remain 
unclear (4), however similar clinical and metabolic mechanisms appear to be involved in the 
pathogenesis of PCOS and EC.  These include obesity, unopposed estrogen, 
hyperandrogenism and hyperinsulinaemia (5).  Recent studies linking aberrant regulation of 
intracellular lipogenesis in EC, (6) through up-regulation of Sterol Regulatory Element 
Binding Protein-1 (SREBP1), suggest that this pathway might also play a role in modulating 
the risk of EC in women with PCOS.  There have however been no previous studies 
investigating endometrial expression of SREBP1 in women with PCOS. 
SREBP is a gene that regulates lipogenesis. Its expression is regulated by the insulin and 
sterol levels in the cell. In mammalian cells, three isoforms of SREBP have been identified, 
namely SREBP1a, SREBP1c and SREBP2. Although there is some overlap in their function 
and pathways, studies have shown that SREBP1 plays a role in fatty acid synthesis and 
metabolism, whereas SREBP2 is involved in cholesterol regulation (7,8). A recent study 
revealed that the expression of Silent Information Regulator-1 (SIRT1) and SREBP1 were up-
regulated in the endometrium of EC women compared to normal endometrium (9). This de 
novo lipogenesis is known to be pathognomonic in cancer cell growth (10). Interestingly, the 
role of SREBP1 is not only confined to lipid synthesis but this gene has also been found to 
activate the Phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway, which 
synergistically promotes cell proliferation and growth (11). Prior to commencing the 
recruitment for our study, we identified one published study investigating SREBP1a and 
SREBP 1c genetic variation in blood from women with PCOS, which found no association 
(12). There had however, been no study investigating endometrial SREBP1 expression in 
PCOS and clinical or biochemical correlations with its endometrial expression.  Our study 
therefore aimed to investigate the association between PCOS and EC by measuring 
endometrial SREBP1 gene expression in PCOS and EC women compared with controls.  We 
also evaluated clinical and biochemical correlations with endometrial SREBP1 gene 
expression levels.  This was considered an important additional building block to increase our 
understanding of the complex web of molecular interactions that increase EC risk in women 
with PCOS. Understanding these interactions could also justify the facilitation of EC 
prevention strategies by suppression of lipid synthesis in women with PCOS. 
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Material and methods  
 
A cross sectional study was performed at Nottingham University Hospital, in the UK 
following Research Ethics (institutional review board) approval from the National Research 
Ethics Service, East Midlands-Northampton committee (13/EM/0119). Part of this project 
investigating the insulin signaling pathways has been published (13). 
 
As published (13), a total of 102 participants were recruited into three groups (women with 
PCOS, women with EC and controls) with 34 participants, in each group. Women with PCOS 
were diagnosed using the Rotterdam criteria (14) and aged between 18 to 45 years. In the EC 
group, the endometrial histology results confirmed endometroid adenocarcinoma (type 1), 
before they were recruited in this study. Women with any evidence of metachronous/ 
synchronous tumour and/ or previous chemo/ radiotherapy were excluded prior to 
recruitment. The control group consisted of women without PCOS and without EC who were 
scheduled for elective gynecological or a pelvic surgical procedure for benign (non-
malignant) indications.  
 
Participants were assessed clinically with measurements taken of their blood pressures, 
weight (kilograms), height (metres), body mass index (BMI), and waist-hip circumference. 
Hormonal and biochemical profiles (testosterone, sex hormone binding globulin (SHBG), 
follicle stimulating hormone (FSH), luteinizing hormone (LH), prolactin, thyroid hormones, 
fasting blood sugar, high density lipoprotein (HDL), low density lipoprotein (LDL) and 
triglycerides) were measured following a venipuncture.   Endometrial tissue biopsy for PCOS 
group was obtained using a Pipelle® endometrial catheter for histology and gene expression 
analysis.  The samples were snap frozen in liquid nitrogen at minus 80 degrees Celsius and 
stored in freezer at minus 160 degrees Celsius until analysis. For the EC tissue sampling, the 
whole surgical specimen following hysterectomy was transferred to the histology pathology 
laboratory immediately, where a designated pathologist performed a gross examination of the 
specimen. The uterus was bisected and endometrial surface inspected. Following that, a small 
cut of the endometrial tissue (0.5x0.5cm) was performed and the sample was handed to the 
researcher in a 1.5 ml tube. The tube was immersed in liquid nitrogen at minus 80 degrees 
Celsius.  The sample was then transported to the laboratory for storage in a freezer at minus 
160 degrees Celsius until future analysis.   
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The control group consisted of women who were identified and recruited from the outpatient 
gynecology clinics, at Queen’s Medical Centre, Nottingham. They were diagnosed with 
benign gynecology disorders (for example uterine fibroids, ovarian cysts or were scheduled 
for bilateral tubal ligation for contraception), and endometrial samples were obtained during 
the planned operative procedure following their consent. Prior to surgery, venepunctures, for 
endocrine and biochemical assays were also performed.   
 
The Cobas 8000® System by Roche (West Sussex, UK) was used for the measurement of 
fasting blood sugar level and lipid profiles. For hormonal analysis (FSH, LH and 
testosterone), an immunoassay method was used using the Architect 12000SR® equipment 
by Abbott (Chicago, USA). Various verification methods which included precision, accuracy, 
linearity and method comparison studies were performed to ensure validity of the results.  
 
The tissue samples obtained during the operative procedures were fixed in 10% buffered 
formalin. Then, the tissues were cut into thin sections. The sections were later paraffin-
embedded after graded ethanol dehydration process and paraffin infiltration. Thin tissue 
sections ranging between 3 to 10 microns in thickness were cut from the paraffin block using 
a microtome. The slices of tissue sections were then stained with hematoxylin and eosin 
(H&E), and mounted on a glass slide. The slices were covered with a thin glass cover to seal 
the preparation. The sections were examined using a Carl Zeiss light microscope 
(Oberkochen, Germany). 
 
The QIA shredder kit, Qiagen® (Hilden, Germany) was used for endometrial tissue 
disruption and homogenization, for RNA extraction. Following that, the RNA was purified 
using the QIAamp Mini-kit, Qiagen® (Hilden, Germany). The Superscript® III First-Strand 
Synthesis System, Invitrogen TM (California, USA) was utilized for reverse transcription 
process (13). Real-time q-PCR was performed using Taqman® qPCR Gene Expression 
Master Mix (Life Technologies) (California, USA) as described in our previous publication 
(13). The life cycler 480® (California, USA) machine was used to perform the q-PCR 
analysis. Beta-actin (ACTB) was selected as a housekeeping gene (13) to normalize 
differences in the quantity of RNA in each sample in comparison to the gene of interest 
(SREBP1). To ensure a high degree of precision, every sample was made in triplicate. The 
ratio of gene expression was calculated using this formula, (E target) ΔCt target (control-treated)/ (E 
ref) ΔCt ref (control-treated) 
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Statistical analyses 
GraphPad Prism 6® (GraphPad Software, San Diego, CA, USA) and SPSS version 21 (IBM 
Corp., Armonk, NY, USA) were used for statistical calculation.  The normality test was 
checked using the Shapiro normality test. A one-Way-ANOVA test or independent T-test 
was performed to compare demographic data for any statistically significant differences 
between the groups. Confounding factors (e.g. age and weight) were adjusted to ensure a 
reliable correlation test.  Means ± standard deviations were used to summarize normally 
distributed continuous variables, whilst medians ± range, were used for variables that were 
not normally distributed. The Spearman correlation coefficient test was used to correlate 
independent variables.  A p-value of less than 0.05 was set as statistical significance. 
 
Results 
 
Participant characteristics 
Although the mean BMI of women with PCOS (29.28 (±2.91) kg/m2) and controls (28.58 
(±2.62) kg/m2) was not significantly different, women with EC had a higher mean BMI 
(32.22(±5.70) kg/m2). The mean age for PCOS was however younger (31.8 (±5.97) years) 
compared to women with EC (63.44 (±10.07) years) and controls (43.68 (±13.12) years). 
Although PCOS participants were recruited during their proliferative menstrual phase (based 
on their menstrual history), histologically two women had secretory phase endometrium and 
eight samples were inadequate. However majority (24 PCOS women) were in the 
proliferative phase. All EC participants had endometroid adenocarcinoma, with moderately 
differentiated (G2) most prevalent, 44.1%, followed by poorly differentiated (G3) (29.4%) 
and well differentiated (G1) (26.5%). The waist-hip ratio (WHR) was positively correlated 
with insulin resistance (homeostatic model assessment of insulin resistance (HOMA-IR)) 
with p=0.011, in EC however it was not significant in PCOS (p=0.245) (13).  
 
SREBP1 Expression 
The expression of SREBP1 gene in the endometrium was significantly increased in PCOS 
and EC women (p<0.0001) compared to controls. Even though in EC the expression was 
lower compared to PCOS this was not statistically significant (p=0.067) (Figure 1). The 
Spearman correlation coefficient test was performed to determine the correlation between 
SREBP1 expression with clinical and biochemical parameters. SREBP1 gene expression was 
positively correlated with BMI in PCOS (r=0.289, p=0.336) and EC (r=0.643, p=0.006) but 
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this was only statistically significant in EC women. WHR was also not significantly 
correlated with SREBP1 expression in PCOS and EC with p=0.544 and p=0.086 respectively. 
HOMA-IR was significantly correlated with SREBP1 gene expression in PCOS but not EC. 
 
Correlation between SREBP1 expression and lipid profiles 
Apart from HDL cholesterol levels, all serum lipid parameters had a positive correlation with 
endometrial SREBP1 gene expression in both PCOS and EC. However, only triglyceride 
levels were significant correlated with SREBP1 gene expression in both PCOS and EC 
(p<0.05). Table 1 illustrates these findings. 
 
SREBP1 serum validation using ELISA immunoassay  
Serum SREBP1 protein concentration was significantly higher in PCOS compared to controls 
(p=0.046). Similarly, the protein concentration was higher in EC compared to controls 
(p=0.008). There was no significant difference in serum SREBP1 protein concentrations 
between PCOS and EC (p=0.346). Figure 2 illustrates the concentration of SREBP1 protein in 
the serum of PCOS and EC compared to controls. 
 
Discussion  
 
This study investigates endometrial SREBP1 gene expression (a gene that regulates lipid 
synthesis) in women with EC, PCOS and controls. This gene expression has been shown to 
be independent of menstrual cycle phase and estrogen levels in circulation (15). We find that 
endometrial SREBP1 gene expression is markedly increased in PCOS and EC women 
compared to endometrium in women without EC and without PCOS. The hypothesis that 
endometrial SREBP1 gene expression level is raised in women with PCOS and EC compared 
to controls is based on the observation that hyperlipidaemia, metabolic syndrome and insulin 
resistance are pertinent risk factors present in EC and in the majority of women with PCOS 
(16).  
 
Previous studies have found that SREBP1 gene is up-regulated and supports cell growth and 
proliferation in cancer cells (17).  SREBP1 has not only been found to be highly expressed in 
EC cells and atypical endometrial hyperplasia (18) but also in hepatocellular cancer (19). 
Knocking down SREBP1 by shRNA achieved almost complete reduction of colonies in their 
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clonogenic assays of endometrial tumour and inhibition of this gene leads to cell death and 
apoptosis (18,20). Increased SREBP1 gene expression may therefore be associated with an 
increased risk of EC in PCOS. 
 
As far as we know, our study is the first study that investigates endometrial gene expression 
of SREBP1 in PCOS endometrium.  A previous study has however investigated genetic 
variations in SREBP1 gene obtained from whole blood samples, in a cohort of 153 PCOS 
women in order to explain different PCOS phenotypes, but did not identify any variations 
(12). 
 
In our study, although the BMI of women with PCOS and controls are not significantly 
different, women with EC have a higher mean BMI. A significant positive correlation of 
SREBP1 expression to BMI and triglyceride in EC is also present. These findings are 
consistent with the finding of a 6.25 fold increased risk of EC among obese compared non-
obese women (21). A previous study (22) investigating the correlation of WHR (instead of 
BMI alone), a marker of abdominal fat distribution, with the risk of EC found that after 
adjusting for BMI, a waist circumference of more than 88 cm was a significant risk of EC.  
SREBP1 expression is therefore probably associated with central obesity and insulin 
resistance as found in PCOS rather than BMI alone. In our study however, although SREBP1 
gene expression is positively correlated with WHR, this correlation is not statistically 
significant.   On the other hand, SREBP1 gene expression is significantly correlated with 
triglyceride and insulin resistance (HOMA-IR) in PCOS women. In a study of  insulin-like 
growth factor-1 ( IGF1), insulin-like growth factor binding protein 1(IGFBP1) and 
phosphatase and tensin homolog (PTEN) genes which are involved in the insulin signaling 
pathway, in endometrial biopsies taken from the women recruited into our study (13), we 
found that the pattern of over expression of IGF1, IGFBP1 and PTEN also mirrored the over 
expression of SREBP1 outlined in this paper.  These interactions between fatty acid 
metabolism, insulin resistance, obesity and EC risk in PCOS clearly require more detailed 
evaluation.   
 
The indirect effect of SREBP1 on the IGF1 pathways and the promotion of cell growth and 
proliferation is an interesting observation. Experiments on sebaceous cell line models reveal 
that IGF1 stimulates the expression of both SREBP1 protein and lipogenesis (23,24). It is also 
well documented that IGF1 is crucial in the development of many cancers and its expression 
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is related to the cancer grade and poor prognostic outcome (25, 26, 27). Therapeutic 
strategies to prevent EC risk in PCOS should therefore ideally explore not only IGF1 but 
strategies synergistically blocking SREBP1 receptors as well.  However the effect of lipid 
lowering drugs in PCOS for EC prevention or concurrent use of lipid lowering agents and 
agents targeting IGF1 in preventing EC in PCOS has not previously been investigated.  This 
is particularly important, given increasing evidence on the use of insulin sensitizing agent 
(metformin) to regulate IGF1 in EC cells (28). 
 
The strengths of our study are in its originality, the rigorous phenotyping of patients and the 
robust endocrine, metabolic and gene expression experiments.  It would have been ideal to 
possibly explore genome-wide, proteomic and metabolomics expression studies in parallel, to 
facilitate a more robust pathway analysis of molecules, possibly involved in modulating EC 
risk in PCOS including the specific role of SREBP1 in this pathway.  This was however not 
considered feasible in the context of the available resources.   
 
In conclusion, in our study, SREBP1 gene expression is significantly increased in the 
endometrium of women PCOS and EC compared with controls, although the BMI of women 
with PCOS and controls are not significantly different.  Women with EC however have a 
higher mean BMI than women with PCOS and EC.  Although this can be interpreted as 
evidence that elevated SREBP1 in our study is independent of obesity, an association between 
SREBP1 gene expression and BMI, WHR, HOMA-IR, and lipid profiles is present. These 
interactions between intra-cellular lipogenesis, insulin resistance, obesity and EC risk in 
PCOS clearly require more detailed evaluation.  There may also be a role for using lipid 
lowering drugs (alone in combination with agents targeting insulin resistance) to prevent EC 
in women with PCOS.  More studies are however required to validate these findings and test 
these hypotheses.   
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Figure legends 
 
Table 1: Spearman correlation coefficient test with *p value <0.05 is significant. PCOS, 
polycystic ovary syndrome; EC, endometrial cancer; LDL, low density lipoprotein; HDL, 
high density lipoprotein; TG, triglyceride; Total Chol, total cholesterol. 
 
Figure 1: Relative SREBP1 and ACTB expression in polycystic ovary syndrome (PCOS) and 
endometrial cancer (EC) compared to controls. 
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Figure 2: The concentration of serum SREBP1 in the controls, polycystic ovary syndrome 
(PCOS) and endometrial cancer (EC). 
 
 
Table 1: Spearman correlation coefficient test with *p value <0.05 is significant. LDL: Low 
density lipoprotein; HDL: High density lipoprotein; TG: Triglyseride; Total Chol: Total 
cholesterol. 
 
 
            Groups/ 
Parameters 
PCOS EC 
r value P-value r value P-value 
LDL 0.79 0.008 0.045 0.855 
HDL -0.143 0.587 0.09 0.705 
TG 0.757 0.004* 0.539 0.027* 
Total Chol 0.176 0.562 0.196 0.441 
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